ClinicalTrials.gg
CompletedNCT00196326Updated Nov 16, 2016Results posted

Open-label Study to Evaluate the Efficacy and Safety of an Extended-cycle, Low Dose Combination Oral Contraceptive

A Phase 3 interventional study of DR-1011 in Contraception, sponsored by Duramed Research. Completed at 55 sites in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-16.

Sponsored by Duramed Research (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,235
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

This is an open-label, single treatment study. All subjects will receive one year of oral contraceptive therapy with DR-1011. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary.

02

Conditions studied

  • Contraception

Keywords

  • pregnancy prevention
  • oral contraceptives
03

In context

Lead sponsor

Duramed Research is the lead sponsor of 24 studies on the registry; none are open to participants now.

First submitted before Duramed Research became part of Teva Pharmaceutical Industries, Ltd..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Premenopausal
  • Not pregnant or breastfeeding
  • Sexually active at risk of pregnancy

Exclusion criteria

Exclusion Criteria:

  • Any to the use of oral
  • Pregnancy within the last 3 months
  • Smoking > 10 cigarettes per day
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,235 participants (actual)

Study arms

  • Experimental
    DR-1011

    Participants were instructed to take, by mouth, one tablet daily for four 91-day cycles.

    Drug: DR-1011

Interventions

  • DrugDR-1011

    Drug pages: Levonorgestrel · Ethinyl Estradiol

    Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).

    Also known as: levonorgestrel/ethinyl estradiol

06

What researchers measure

Primary outcomes

  1. Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining "On Drug" Pregnancy

    Pearl Index= ((100)\*(number of pregnancies)\*(4 cycles/year))/number of 91-day cycles completed. The pregnancy rate included "on-drug" pregnancies, defined as those pregnancies for which the date of conception was on or after the date of first dose of study medication, but no more than 14 days after the date of last combination dose of study medication. Pregnancy was defined as a positive pregnancy test verified by the study staff. The conception date was based on the ultrasound date. A pregnancy was not considered 'on drug' if conception clearly occurred prior to first dose of study medication, or more than 14 days after the date of last combination dose of study medication. Three denominators are reported; * excluding cycles where other birth control methods (BCMs) was used * all complete cycles * compliant-use (i.e. subject did not skip two or more consecutive pills or had a pattern of substantial non-compliance, or used a prohibited concomitant medication)

    Time frame: up to one year

  2. Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 7 Days Post-Last Combination Dose When Defining "On Drug" Pregnancy

    Pearl Index= ((100)\*(number of pregnancies)\*(4 cycles/year))/number of 91-day cycles completed. The pregnancy rate included "on-drug" pregnancies, defined as those pregnancies for which the date of conception was on or after the date of first dose of study medication, but no more than 7 days after the date of last combination dose of study medication. Pregnancy was defined as a positive pregnancy test verified by the study staff. The conception date was based on the ultrasound date. A pregnancy was not considered 'on drug' if conception clearly occurred prior to first dose of study medication, or more than 7 days after the date of last combination dose of study medication. Three denominators are reported; * excluding cycles where other birth control methods (BCMs) was used * all complete cycles * compliant-use (i.e. subject did not skip two or more consecutive pills or had a pattern of substantial non-compliance, or used a prohibited concomitant medication)

    Time frame: up to one year

Secondary outcomes

  1. Participants With Treatment-Emergent Adverse Events

    Safety was assessed by summarizing adverse events recorded in the patient's daily diary and reported by subjects at each study visit, and by summarizing results of examination, vital signs and clinical laboratory values.

    Time frame: Day 1 up to one year

07

Results

Posted Apr 15, 2009

Participant flow

Participant flow — Overall Study
MilestoneDR-1011
Started2235
Safety population2185
Pregnancy intent-to-treat cohort (pitt)1735
Completed1249
Not completed986
Withdrew: Did not meet protocol requirements64
Withdrew: Non-compliance with the protocol81
Withdrew: Physician decision3
Withdrew: Withdrawal by subject225
Withdrew: Adverse event253
Withdrew: Pregnancy34
Withdrew: Lost to follow-up304
Withdrew: Other22

Outcome measures

PrimaryAnnualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining "On Drug" Pregnancy

Pearl Index= ((100)\*(number of pregnancies)\*(4 cycles/year))/number of 91-day cycles completed. The pregnancy rate included "on-drug" pregnancies, defined as those pregnancies for which the date of conception was on or after the date of first dose of study medication, but no more than 14 days after the date of last combination dose of study medication. Pregnancy was defined as a positive pregnancy test verified by the study staff. The conception date was based on the ultrasound date. A pregnancy was not considered 'on drug' if conception clearly occurred prior to first dose of study medication, or more than 14 days after the date of last combination dose of study medication. Three denominators are reported; * excluding cycles where other birth control methods (BCMs) was used * all complete cycles * compliant-use (i.e. subject did not skip two or more consecutive pills or had a pattern of substantial non-compliance, or used a prohibited concomitant medication)

Time frame:
up to one year
Reported as:
Number · pregnancies per 100 woman years exposure
Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining "On Drug" Pregnancy
pregnancies per 100 woman years exposureDR-1011
Excluding other BCMs (n=1732)2.44
All complete cycles (n=1735)2.42
Compliant-Use (n=1685)1.77
SecondaryParticipants With Treatment-Emergent Adverse Events

Safety was assessed by summarizing adverse events recorded in the patient's daily diary and reported by subjects at each study visit, and by summarizing results of examination, vital signs and clinical laboratory values.

Time frame:
Day 1 up to one year
Reported as:
Number · participants
Participants With Treatment-Emergent Adverse Events
participantsDR-1011
Participants With Treatment-Emergent Adverse Events1742
PrimaryAnnualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 7 Days Post-Last Combination Dose When Defining "On Drug" Pregnancy

Pearl Index= ((100)\*(number of pregnancies)\*(4 cycles/year))/number of 91-day cycles completed. The pregnancy rate included "on-drug" pregnancies, defined as those pregnancies for which the date of conception was on or after the date of first dose of study medication, but no more than 7 days after the date of last combination dose of study medication. Pregnancy was defined as a positive pregnancy test verified by the study staff. The conception date was based on the ultrasound date. A pregnancy was not considered 'on drug' if conception clearly occurred prior to first dose of study medication, or more than 7 days after the date of last combination dose of study medication. Three denominators are reported; * excluding cycles where other birth control methods (BCMs) was used * all complete cycles * compliant-use (i.e. subject did not skip two or more consecutive pills or had a pattern of substantial non-compliance, or used a prohibited concomitant medication)

Time frame:
up to one year
Reported as:
Number · pregnancies per 100 woman years exposure
Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 7 Days Post-Last Combination Dose When Defining "On Drug" Pregnancy
pregnancies per 100 woman years exposureDR-1011
Excluding other BCMs (n=1732)2.15
All complete cycles (n=1735)2.12
Compliant-Use (n=1685)1.77

Adverse events

Collected over Day 1 up to one year. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DR-1011—34/2,185 (1.6%)1,333/2,185 (61%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventDR-1011
ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions4/2185
APPENDICITISInfections and infestations2/2185
ASTHMARespiratory, thoracic and mediastinal disorders2/2185
CHOLELITHIASISHepatobiliary disorders2/2185
ABDOMINAL PAIN UPPERGeneral disorders1/2185
ABORTION MISSEDPregnancy, puerperium and perinatal conditions1/2185
BILIARY DILATATIONHepatobiliary disorders1/2185
BILIARY DYSKINESIAHepatobiliary disorders1/2185
CERVICOBRACHIAL SYNDROMENervous system disorders1/2185
CHOLECYSTITISHepatobiliary disorders1/2185
Most frequent other events
Most frequent other events
EventDR-1011
HEADACHENervous system disorders732/2185
NASOPHARYNGITISInfections and infestations362/2185
DYSMENORRHOEAReproductive system and breast disorders250/2185
NAUSEAGastrointestinal disorders190/2185
METRORRHAGIAReproductive system and breast disorders183/2185
BACK PAINMusculoskeletal and connective tissue disorders175/2185
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations174/2185
SINUSITISInfections and infestations157/2185
URINARY TRACT INFECTIONInfections and infestations118/2185

Baseline characteristics

Safety population

Age, Continuous
Age, Continuous(years)DR-1011
Mean27.7 ± 5.80
Sex: Female, Male
Sex: Female, Male(Participants)DR-1011
Female2185
Male0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)DR-1011
African-American256
Asian36
Caucasian1627
Hispanic218
Other48
Region of Enrollment
Region of Enrollment(participants)DR-1011
United States2185
Weight
Weight(pounds)DR-1011
Mean158.7 ± 41.26
Body Mass Index
Body Mass Index(kg/m^2)DR-1011
Mean26.7 ± 6.65
08

Study locations

55 sites
  • Duramed Investigational Site
    Huntsville, Alabama 35801, United States
  • Duramed Investigational Site
    Phoenix, Arizona 85013, United States
  • Duramed Investigational Site
    Phoenix, Arizona 85031, United States
  • Duramed Investigational Site
    Phoenix, Arizona 85032, United States
  • Duramed Investigational Site
    Tucson, Arizona 85712, United States
  • Duramed Investigational Site
    San Diego, California 92103, United States
  • Duramed Investigational Site
    San Diego, California 92108, United States
  • Duramed Investigational Site
    Colorado Springs, Colorado 80907, United States
  • Duramed Investigational Site
    Colorado Springs, Colorado 80909, United States
  • Duramed Investigational Site
    Denver, Colorado 80202, United States
  • Duramed Investigational Site
    New London, Connecticut 06320, United States
  • Duramed Investigational Site
    Coral Cables, Florida 33134, United States
  • Duramed Investigational Site
    Hollywood, Florida 33024, United States
  • Duramed Investigational Site
    Jacksonville, Florida 32216, United States
  • Duramed Investigational Site
    Leesburg, Florida 34748, United States
  • Duramed Investigational Site
    Miami, Florida 33143, United States
  • Duramed Investigational Site
    Palm Springs, Florida 33437, United States
  • Duramed Investigational Site
    Sarasota, Florida 34239, United States
  • Duramed Investigational Site
    Tampa, Florida 33607, United States
  • Duramed Investigational Site
    Decatur, Georgia 30034, United States
  • Duramed Investigational Site
    Douglasville, Georgia 30134, United States
  • Duramed Investigational Site
    Boise, Idaho 83704, United States
  • Duramed Investigational Site
    Chicago, Illinois 60611, United States
  • Duramed Investigational Site
    Shawnee Mission, Kansas 66216, United States
  • Duramed Investigational Site
    Topeka, Kansas 66614, United States
  • Duramed Investigational Site
    Louisville, Kentucky 40291, United States
  • Duramed Investigational Site
    Kansas City, Missouri 64106, United States
  • Duramed Investigational Site
    St. Louis, Missouri 63110, United States
  • Duramed Investigational Site
    Lawrenceville, New Jersey 08648, United States
  • Duramed Investigational Site
    Moorestown, New Jersey 08057, United States
  • Duramed Investigational Site
    New Brunswick, New Jersey 08901, United States
  • Duramed Investigational Site
    Rochester, New York 14609, United States
  • Duramed Investigational Site
    Charlotte, North Carolina 28222, United States
  • Duramed Investigational Site
    Wilmington, North Carolina 28412, United States
  • Duramed Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • Duramed Investigational Site
    Columbus, Ohio 43205, United States
  • Duramed Investigational Site
    Columbus, Ohio 43213, United States
  • Duramed Investigational Site
    Oklahoma, Oklahoma 73112, United States
  • Duramed Investigational Site
    Medford, Oregon 97504, United States
  • Duramed Investigational Site
    Philadelphia, Pennsylvania 19114, United States
  • Duramed Investigational Site
    Pittsburgh, Pennsylvania 15206, United States
  • Duramed Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • Duramed Investigational Site
    Willow Grove, Pennsylvania 19090, United States
  • Duramed Investigational Site
    Dallas, Texas 75390, United States
  • Duramed Investigational Site
    Houston, Texas 77030, United States
  • Duramed Investigational Site
    San Antonio, Texas 78229, United States
  • Duramed Investigational Site
    Waco, Texas 76712, United States
  • Duramed Investigational Site
    Salt Lake City, Utah 84124, United States
  • Duramed Investigational Site
    Newport News, Virginia 23602, United States
  • Duramed Investigational Site
    Norfolk, Virginia 23507, United States
  • Duramed Investigational Site
    Richmond, Virginia 23226, United States
  • Duramed Investigational Site
    Lakewood, Washington 98499, United States
  • Duramed Investigational Site
    Seattle, Washington 98105, United States
  • Duramed Investigational Site
    Spokane, Washington 99207, United States
  • Duramed Investigational Site
    Tacoma, Washington 98405, United States
09

References and documents

Publications

  • Kroll R, Reape KZ, Margolis M. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol. Contraception. 2010 Jan;81(1):41-8. doi: 10.1016/j.contraception.2009.07.003. PubMed 20004272 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Jun 2007 and a completion of Jun 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2009, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 20, 2005
Start
Jun 2005
Primary completionActual
Jun 2007
CompletionActual
Jun 2007
Results first posted
Apr 15, 2009
Last update
Nov 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00196326
Lead sponsor
Duramed Research
First posted
Sep 20, 2005
Start date
Jun 2005
Primary completion
Jun 2007
Completion
Jun 2007
Results posted
Apr 15, 2009
Last update
Nov 16, 2016

Study contacts

Duramed Protocol Chair
study chair · Duramed Research, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levonorgestrel · Ethinyl Estradiol

Start the discussion